Skip to content
Screener

Aebi Schmidt Holding AEBI Europe and ROW — R&D

Other segment segments

North America
$1.63M+172%

Similar metrics at other companies

Brady Corporation logo
BRCEurope & Australia — R&D
$6.58M+12.0%
Insmed logo
INSMARIKAYCE external R&D expenses — R&D
$6.23M-43.4%
Insmed logo
INSMBrensocatib external R&D expenses — R&D
$13.83M-58.8%
Insmed logo
INSMTPIP external R&D expenses — R&D
$38.94M+88.6%
Insmed logo
INSMOther external R&D expenses — R&D
$48.84M+71.7%
Micron Technology logo
MUAEBU — R&D
$109M+0.9%

Other financials

Income statement

See full
Revenue$455.5M+82.8%
Gross profit$87.4M+63.9%
Operating income$15.4M+6.8%
Net income$695.0K-66.5%
EPS (diluted)$0.01-80.0%

Balance sheet

See full
Cash & equivalents$115.9M+142%
Total debt$794.1M+52.8%
Total equity$814.7M+119%
Total assets$2.0B+79.7%

Cash flow

See full
Operating cash flow-$17.7M+33.2%
CapEx$1.9M-37.8%
Free cash flow-$19.7M+33.7%

Valuation

See full
Market cap$1.02B+17.8%
Enterprise value$1.69B
P/E121.6×
P/S0.6×

Profitability

See full
Gross margin19.5%-1.2pp
Operating margin4.3%-1.6pp
Net margin0.5%-1.7pp
FCF margin3.3%+2.8pp

Returns & leverage

See full
Return on equity1.4%-5.3pp
Debt / equity-0.4×
Current ratio-0.1×

Where this comes from

Reported directly by Aebi Schmidt Holding in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Aebi Schmidt Holding’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 7:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034785
Line itemThree Months Ended March 31, 2026 / North AmericaThree Months Ended March 31, 2026 / Europe and ROWThree Months Ended March 31, 2025 / North AmericaThree Months Ended March 31, 2025 / Europe and ROW
Sales$337,322$118,223$147,291$101,895
Cost of products sold276,03592,121116,90978,971
Research and development1,6335,0686014,026
Selling, general and administrative39,32219,22512,53418,190
Other segment items(1)(6,031)(4,945)(1,789)(1,533)
Segment Adjusted EBITDA$26,363$6,754$19,036$2,241

Item 1. Financial Statements.

FAQ

What is Aebi Schmidt Holding's europe and ROW — R&D?
Aebi Schmidt Holding (AEBI) reported europe and ROW — R&D of $5.07M in Q1 2026.
How has Aebi Schmidt Holding's europe and ROW — R&D changed year-over-year?
Aebi Schmidt Holding's europe and ROW — R&D increased by 25.9% year-over-year, from $4.03M to $5.07M.
What does europe and ROW — R&D mean?
This metric captures the expenses incurred by the Europe and Rest of World segment for the discovery and development of new products, services, or processes. It reflects the segment's commitment to innovation and long-term competitive positioning in its regional markets.

Ask your AI about Aebi Schmidt Holding's europe and row — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude